These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 36202642)
1. Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study using national population data. Silva-Valencia J; Soto-Becerra P; Escobar-Agreda S; Fernandez-Navarro M; Elorreaga OA; Mayta-Tristán P; Mezones-Holguin E; Solari L Vaccine; 2022 Oct; 40(45):6512-6519. PubMed ID: 36202642 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru. Vargas-Herrera N; Fernández-Navarro M; Cabezudo NE; Soto-Becerra P; Solís-Sánchez G; Escobar-Agreda S; Silva-Valencia J; Pampa-Espinoza L; Bado-Pérez R; Solari L; Araujo-Castillo RV PLoS One; 2022; 17(10):e0268419. PubMed ID: 36251630 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study. Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402 [TBL] [Abstract][Full Text] [Related]
5. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data. Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon. Moghnieh R; Mekdashi R; El-Hassan S; Abdallah D; Jisr T; Bader M; Jizi I; Sayegh MH; Rahman Bizri A Vaccine; 2021 Nov; 39(46):6713-6719. PubMed ID: 34656379 [TBL] [Abstract][Full Text] [Related]
7. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605 [TBL] [Abstract][Full Text] [Related]
8. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial. Batmunkh T; Moore KA; Thomson H; Altangerel B; Amraa O; Avaa N; Batbayar L; Batsukh K; Bright K; Burentogtokh T; Ha Do LA; Dorj G; Hart JD; Javkhlantugs K; Jigjidsuren S; Justice F; Li S; Licciardi PV; Mashbaatar K; Mazarakis N; Neal EFG; Nguyen CD; Ochirbat B; Tsolmon B; Tuya A; Surenjav U; von Mollendorf C; Mulholland K Lancet Reg Health West Pac; 2024 Jan; 42():100953. PubMed ID: 38357398 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia. Petrović V; Vuković V; Patić A; Marković M; Ristić M PLoS One; 2022; 17(2):e0263468. PubMed ID: 35108321 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals. Eybpoosh S; Biglari A; Sorouri R; Ashrafian F; Sadat Larijani M; Verez-Bencomo V; Toledo-Romani ME; Valenzuela Silva C; Salehi-Vaziri M; Dahmardeh S; Doroud D; Banifazl M; Mostafavi E; Bavand A; Ramezani A PLoS Pathog; 2023 Nov; 19(11):e1011744. PubMed ID: 37910480 [TBL] [Abstract][Full Text] [Related]
13. Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine. Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N Expert Rev Vaccines; 2022 Dec; 21(12):1873-1881. PubMed ID: 35792752 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study. Petrović V; Vuković V; Patić A; Marković M; Ristić M Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679901 [TBL] [Abstract][Full Text] [Related]
15. The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series. Angkasekwinai N; Niyomnaitham S; Sewatanon J; Phumiamorn S; Sukapirom K; Senawong S; Toh ZQ; Umrod P; Somporn T; Chumpol S; Ritthitham K; Jantraphakorn Y; Srisutthisamphan K; Chokephaibulkit K Asian Pac J Allergy Immunol; 2023 Jul; ():. PubMed ID: 37466962 [TBL] [Abstract][Full Text] [Related]
16. Immediate Adverse Reaction and SARS-CoV-2 Anti-Spike Receptor Binding Domain IgG of COVID-19 Vaccines Among Health Staffs. Rasheed WS; Sarkees AN Disaster Med Public Health Prep; 2024 Apr; 18():e66. PubMed ID: 38618867 [TBL] [Abstract][Full Text] [Related]
17. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel. Park S; Gatchalian KK; Oh H Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010 [TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study. Paternina-Caicedo A; Quevedo DS; Ríos DS; Moyano D; Alvis-Guzmán N; Alviz-Zakzuk NR; Salcedo F; Moyano L; Ramírez-Suarez J; Smith AD; De la Hoz-Restrepo F Vaccine; 2023 Oct; 41(42):6291-6299. PubMed ID: 37679278 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Sinopharm's BBIBP-CorV Booster Vaccination against COVID-19-Related Severe and Critical Cases and Deaths in Morocco during the Omicron Wave. Belayachi J; Mhayi A; Majidi H; El Fahime E; Abouqal R Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543878 [TBL] [Abstract][Full Text] [Related]
20. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization. Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]